Health X Platfor

Who are the top shareholders of the Sastasundar Ven.?

The top shareholder of Sastasundar Ven. is Banwari Lal Mittal, holding 33.37%. Other shareholders include four foreign institutional investors with 1.6%, individual investors at 13.7%, and the highest public shareholder, Lekh Raj Juneja, with 1.89%.

The top shareholders of Sastasundar Ven. include the promoters, with Banwari Lal Mittal holding the highest stake at 33.37%. There are no pledged promoter holdings. In terms of institutional investors, the company is held by four foreign institutional investors (FIIs) with a combined holding of 1.6%. Additionally, individual investors collectively own about 13.7% of the shares, while the highest public shareholder is Lekh Raj Juneja, who holds 1.89%. Mutual funds currently hold shares through two schemes, but their stake is negligible at 0.0%.

how big is Sastasundar Ven.?

As of Jun 06, Sastasundar Ventures Ltd has a market capitalization of 878.45 Cr and reported net sales of 1110.95 Cr with a net profit of -91.53 Cr over the latest four quarters. Shareholder's funds are 762.37 Cr, and total assets amount to 1,149.19 Cr as of Mar'24.

Market Cap: As of Jun 06, Sastasundar Ventures Ltd has a market capitalization of 878.45 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which includes data from Mar'25, Dec'24, Sep'24, and Jun'24, is 1110.95 Cr. The sum of Net Profit for the same quarters is -91.53 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending Mar'24. The Shareholder's Funds are reported at 762.37 Cr, and the Total Assets amount to 1,149.19 Cr.

Who are in the management team of Sastasundar Ven.?

As of March 2022, the management team of Sastasundar Ven. includes Banwari Lal Mittal (Chairman & Managing Director), Ravi Kant Sharma, Abha Mittal, Parimal Kumar Chattaraj, Rupanjana De, J. N. Mukhopadhyaya (all Directors), Pratap Singh (Company Secretary), and Anjana Dikshit (Additional Director). Each member contributes to the company's governance and strategic direction.

As of March 2022, the management team of Sastasundar Ven. includes the following individuals:<BR><BR>1. Banwari Lal Mittal - Chairman & Managing Director<BR>2. Ravi Kant Sharma - Director<BR>3. Parimal Kumar Chattaraj - Independent Director<BR>4. Abha Mittal - Director<BR>5. Rupanjana De - Independent Director<BR>6. Pratap Singh - Company Secretary & Compliance Officer<BR>7. J. N. Mukhopadhyaya - Independent Director<BR>8. Anjana Dikshit - Additional Director<BR><BR>Each member plays a vital role in the governance and strategic direction of the company.

Has Sastasundar Ven. declared dividend?

Sastasundar Ventures Ltd has declared a 10% dividend, amounting to ₹1 per share, with an ex-date of July 23, 2012. However, the dividend yield is 0%, and total returns have varied, showing significant gains over the 5-year period despite negative returns in shorter terms.

Sastasundar Ventures Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 23 Jul 12<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -23.17%, the dividend return was 0%, resulting in a total return of -23.17%.<BR><BR>In the 1-year period, the price return was -10.7%, the dividend return was 0%, leading to a total return of -10.7%.<BR><BR>Over the 2-year period, the price return was -6.26%, the dividend return was 0%, which resulted in a total return of -6.26%.<BR><BR>In the 3-year period, the price return was -13.84%, the dividend return was 0%, culminating in a total return of -13.84%.<BR><BR>For the 4-year period, the price return was 20.91%, the dividend return was 0%, giving a total return of 20.91%.<BR><BR>In the 5-year period, the price return was 227.56%, the dividend return was 0%, resulting in a total return of 227.56%.<BR><BR>Overall, while Sastasundar Ventures Ltd declared a dividend, the dividend yield remains at 0%, indicating no additional income from dividends in recent periods. The total returns show a mixed performance, with significant gains over the long term, particularly in the 5-year period, despite negative returns in the shorter terms.

Who are the peers of the Sastasundar Ven.?

Sastasundar Ven.'s peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Prevest Denpro, Nureca, Bilcare, and One Global Serv. One Global Serv leads in 1-year returns at 159.28%, while Sastasundar Ven. has a -14.32% return.

Peers: The peers of Sastasundar Ven. are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Prevest Denpro, Nureca, Bilcare, and One Global Serv.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and One Global Serv, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Average or Below Average ratings. Growth is Excellent for One Global Serv, Average for Sastasundar Ven., Poly Medicure, Indegene, and Nureca, while Below Average growth is noted for Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Prevest Denpro, and Bilcare. In terms of Capital Structure, Excellent ratings are given to Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Sastasundar Ven., Prevest Denpro, Nureca, and One Global Serv, while Bilcare has a Below Average rating.<BR><BR>Return Snapshot: One Global Serv has the highest 1-year return at 159.28%, while Sastasundar Ven. has a 1-year return of -14.32%, which is significantly lower than the highest peer. Additionally, Syngene Intl., Vijaya Diagnost., and Bilcare have negative six-month returns.

What does Sastasundar Ven. do?

Sastasundar Ventures Ltd is a micro-cap company in the healthcare services industry, reporting net sales of ₹2,858 Cr and a net profit of ₹137 Cr for March 2025. It has a market cap of ₹937 Cr, a P/E ratio of 9.00, and a return on equity of 14.79%.

Overview:<BR>Sastasundar Ventures Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 1989 as 'Satyam Fiscal Services Private Limited' and underwent several name changes, becoming 'Microsec Financial Services Limited' in 2005 after converting to a public limited company. The latest quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2,858 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 137 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 937 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 9.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.00 <BR>Return on Equity: 14.79% <BR>Price to Book: 1.36<BR><BR>Contact Details:<BR>Address: Azimganj House 2nd Floor, 7 Abanindra Nath Thakur Sarani Kolkata West Bengal : 700017 <BR>Tel: 91-33-22829330 <BR>Email: info@sastasundar.com <BR>Website: http://www.sastasundarventures.com

How has been the historical performance of Sastasundar Ven.?

Sastasundar Ven.'s historical performance has shown significant fluctuations, with net sales decreasing to 1,110.95 Cr in Mar'25 from 1,375.71 Cr in Mar'24, resulting in a profit after tax of -122.74 Cr in Mar'25, down from 92.03 Cr in Mar'24. The company faced challenges in profitability and asset management during this period.

Answer:<BR>The historical performance of Sastasundar Ven. shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Sastasundar Ven. reported net sales of 1,110.95 Cr in Mar'25, a decrease from 1,375.71 Cr in Mar'24, but an increase from 1,039.81 Cr in Mar'23. The total operating income mirrored this trend, reaching 1,110.95 Cr in Mar'25, down from 1,375.71 Cr in the previous year. The total expenditure, excluding depreciation, was 1,166.98 Cr in Mar'25, down from 1,370.29 Cr in Mar'24. This resulted in an operating profit (PBDIT) of 3.81 Cr in Mar'25, a decline from 65.83 Cr in Mar'24. The profit before tax was -192.86 Cr in Mar'25, compared to 55.68 Cr in Mar'24, leading to a profit after tax of -122.74 Cr in Mar'25, down from 92.03 Cr in Mar'24. The consolidated net profit also fell to -91.17 Cr in Mar'25 from 8.88 Cr in Mar'24. On the balance sheet, total assets decreased to 963.16 Cr in Mar'25 from 1,149.19 Cr in Mar'24, while total liabilities also fell to 963.16 Cr in Mar'25 from 1,149.19 Cr in Mar'24. The cash flow from operating activities was 38 Cr in Mar'24, a recovery from -111 Cr in Mar'23, while the closing cash and cash equivalents increased to 33 Cr in Mar'24 from 31 Cr in Mar'23. Overall, the financial performance of Sastasundar Ven. reflects a challenging environment with notable volatility in profitability and asset management.

Is Sastasundar Ven. technically bullish or bearish?

As of December 3, 2025, Sastasundar Ven's technical trend has shifted to bullish, supported by positive daily moving averages, bullish weekly MACD and KST, and mildly bullish Bollinger Bands, indicating favorable momentum despite no signals from the RSI.

As of 3 December 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The daily moving averages are bullish, and the weekly MACD and KST are also bullish, indicating positive momentum. The Bollinger Bands on both weekly and monthly time frames are mildly bullish, suggesting potential upward movement. Despite the lack of signals from the RSI, the overall technical landscape remains favorable for Sastasundar Ven.

Is Sastasundar Ven. overvalued or undervalued?

As of December 4, 2025, Sastasundar Ven. is considered very expensive and overvalued, with a PE ratio of 14,101.14 and unfavorable comparisons to peers like Bajaj Finance and Life Insurance, suggesting that investors should exercise caution.

As of 4 December 2025, the valuation grade for Sastasundar Ven. has moved from risky to very expensive, indicating a significant shift in its perceived value. The company is currently considered overvalued. Key ratios highlight this concern, with a staggering PE ratio of 14,101.14, an EV to EBIT of -13.69, and an EV to EBITDA of -14.80, all suggesting unsustainable valuations relative to its earnings and cash flows.<BR><BR>In comparison to peers, Sastasundar Ven. stands out unfavorably; for instance, Bajaj Finance has a PE of 34.9 and an EV to EBITDA of 19.63, while Life Insurance boasts a much more attractive PE of 10.85 and an EV to EBITDA of 8.92. These comparisons further reinforce the notion that Sastasundar Ven. is overvalued in the current market context. Despite a recent positive performance over the past month compared to the Sensex, the overall valuation metrics indicate that investors should approach this stock with caution.

When is the next results date for Sastasundar Ventures Ltd?

The next results date for Sastasundar Ventures Ltd is 06 February 2026.

The next results date for Sastasundar Ventures Ltd is scheduled for 06 February 2026.

Are Sastasundar Ventures Ltd latest results good or bad?

Sastasundar Ventures Ltd's latest results are concerning, with a net profit loss of ₹12.69 crores in Q2 FY26, a significant decline in profitability, and negative operating margins. Despite a 10.16% increase in net sales, ongoing operational inefficiencies and persistent losses suggest caution for investors.

Sastasundar Ventures Ltd's latest results indicate a challenging financial situation. In Q2 FY26, the company reported a consolidated net profit loss of ₹12.69 crores, marking a significant decline of 153.07% quarter-on-quarter and an 88.40% drop year-on-year. This is concerning, especially considering that the operating margin (excluding other income) fell to -7.50%, reflecting ongoing operational inefficiencies.<BR><BR>While net sales did show a modest increase of 10.16% year-on-year to ₹301.32 crores, this growth has not translated into profitability. The company has faced persistent losses, with negative operating profits recorded in five of the last seven quarters. Additionally, the return on equity (ROE) is notably low at just 3.66%, which is significantly below industry standards.<BR><BR>Overall, the results suggest that while there is some resilience in revenue growth, the inability to convert sales into sustainable profits, coupled with deteriorating margins and operational challenges, paints a negative picture for Sastasundar Ventures Ltd. Investors should approach the stock with caution given these red flags.

Should I buy, sell or hold Sastasundar Ventures Ltd?

Why is Sastasundar Ventures Ltd falling/rising?

As of 31-May, Health X Platform Ltd's stock price is at 305.05, down 1.1 (-0.36%) and has declined 5.53% over the last three days. Despite positive returns over longer time frames, the stock faces downward pressure due to reduced investor participation and a significant drop in delivery volume.

As of 31-May, Health X Platform Ltd's stock price is currently at 305.05, reflecting a decrease of 1.1 (-0.36%). The stock has been experiencing a downward trend, having fallen for the last three days, resulting in a total decline of 5.53% during this period. Despite this recent drop, the stock has outperformed the sector by 1.3% today.<BR><BR>In terms of performance over various time frames, the stock has shown positive returns over the past week (+0.36%), month (+8.35%), year-to-date (+3.18%), and year (+13.46%). However, the stock's recent performance contrasts with a significant decline in investor participation, as evidenced by a 60.78% drop in delivery volume compared to the 5-day average.<BR><BR>Additionally, while the stock is trading above its moving averages across various time frames (5-day, 20-day, 50-day, 100-day, and 200-day), the falling investor participation suggests a lack of strong buying interest, which may contribute to the current price decline. Overall, the combination of recent losses, reduced trading volume, and the stock's performance relative to the sector indicates that Health X Platform Ltd is currently facing downward pressure.

Which are the latest news on Health X Platfor?